Trial · NCT01150890
Results by group76
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 76
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission at Week 6 | Placebo | 3.1 | percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Remission at Week 6 | Brodalumab 210 mg | 3.1 | percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Remission at Week 6 | Brodalumab 350 mg | 15.2 | percentage of participants | ||
| Percentage of Participants Who Achieved Clinical Remission at Week 6 | Brodalumab 700 mg | 9.1 | percentage of participants | ||
| Percentage of Participants Who Achieved a CDAI Response at Week 6 | Placebo | 12.5 | percentage of participants | ||
| Percentage of Participants Who Achieved a CDAI Response at Week 6 | Brodalumab 210 mg | 16.1 | percentage of participants | ||
| Percentage of Participants Who Achieved a CDAI Response at Week 6 | Brodalumab 350 mg | 27.3 | percentage of participants | ||
| Percentage of Participants Who Achieved a CDAI Response at Week 6 | Brodalumab 700 mg | 15.2 | percentage of participants | ||
| Change From Baseline in CDAI at Week 6 | Placebo | -28.2 | Standard Deviation 86.0 | score on a scale | |
| Change From Baseline in CDAI at Week 6 | Brodalumab 210 mg | -8.7 | Standard Deviation 95.3 | score on a scale | |
| Change From Baseline in CDAI at Week 6 | Brodalumab 350 mg | -35.4 | Standard Deviation 105.6 | score on a scale | |
| Change From Baseline in CDAI at Week 6 | Brodalumab 700 mg | -0.6 | Standard Deviation 105.9 | score on a scale | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | All treatment emergent adverse events (TEAEs) | 25 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 210 mg | All treatment emergent adverse events (TEAEs) | 23 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 350 mg | All treatment emergent adverse events (TEAEs) | 27 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 700 mg | All treatment emergent adverse events (TEAEs) | 28 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | Serious adverse events | 2 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 210 mg | Serious adverse events | 3 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 350 mg | Serious adverse events | 8 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Brodalumab 700 mg | Serious adverse events | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01150890/results